Additional Relevant Details GlycoMimetics announced that its drug candidate GMI-1271 could reduce chemotherapy resistance from multiple myeloma and that it intends to begin clinical trials in Europe in mid-2016.  The drug, when taken with bortezomib, was shown to reduce chemotherapy resistance to bortezomib and could "improve clinical outcomes for high risk and relapsed patients with myeloma".  GMI-1271 is also currently in a Phase 1/2 study evaluating its safety and efficacy when used with chemotherapy in patients with acute myeloid leukemia (AML).